Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An immune cell-selective interleukin 4 agonist.
Shanafelt AB, Forte CP, Kasper JJ, Sanchez-Pescador L, Wetzel M, Gundel R, Greve JM. Shanafelt AB, et al. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9454-8. doi: 10.1073/pnas.95.16.9454. Proc Natl Acad Sci U S A. 1998. PMID: 9689101 Free PMC article.
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo.
Shanafelt AB, Lin Y, Shanafelt MC, Forte CP, Dubois-Stringfellow N, Carter C, Gibbons JA, Cheng SL, Delaria KA, Fleischer R, Greve JM, Gundel R, Harris K, Kelly R, Koh B, Li Y, Lantz L, Mak P, Neyer L, Plym MJ, Roczniak S, Serban D, Thrift J, Tsuchiyama L, Wetzel M, Wong M, Zolotorev A. Shanafelt AB, et al. Among authors: shanafelt mc. Nat Biotechnol. 2000 Nov;18(11):1197-202. doi: 10.1038/81199. Nat Biotechnol. 2000. PMID: 11062441
Receptor-based design of cytokine therapeutics.
Shanafelt AB. Shanafelt AB. Curr Pharm Biotechnol. 2003 Feb;4(1):1-20. doi: 10.2174/1389201033378066. Curr Pharm Biotechnol. 2003. PMID: 12570679 Review.
Therapeutic enhancement of IL-2 through molecular design.
Cassell DJ, Choudhri S, Humphrey R, Martell RE, Reynolds T, Shanafelt AB. Cassell DJ, et al. Among authors: shanafelt ab. Curr Pharm Des. 2002;8(24):2171-83. doi: 10.2174/1381612023393260. Curr Pharm Des. 2002. PMID: 12369861 Review.
Generation of highly selective VPAC2 receptor agonists by high throughput mutagenesis of vasoactive intestinal peptide and pituitary adenylate cyclase-activating peptide.
Yung SL, Dela Cruz F, Hamren S, Zhu J, Tsutsumi M, Bloom JW, Caudle M, Roczniak S, Todd T, Lemoine L, MacDougall M, Shanafelt AB, Pan CQ. Yung SL, et al. Among authors: shanafelt ab. J Biol Chem. 2003 Mar 21;278(12):10273-81. doi: 10.1074/jbc.M211945200. Epub 2003 Jan 13. J Biol Chem. 2003. PMID: 12525492 Free article.
27 results